TCGA-CQ-7072-01A-21R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- ANGIOGENESIS+0.470
- HEDGEHOG_SIGNALING+0.360
- UV_RESPONSE_DN+0.360
- WNT_BETA_CATENIN_SIGNALING+0.350
- NOTCH_SIGNALING+0.280
- MYOGENESIS+0.260
- COAGULATION+0.210
- APICAL_JUNCTION+0.070
- PROTEIN_SECRETION+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.630
- MYC_TARGETS_V2-0.560
- INTERFERON_GAMMA_RESPONSE-0.500
- E2F_TARGETS-0.470
- OXIDATIVE_PHOSPHORYLATION-0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- CHOLESTEROL_HOMEOSTASIS-0.430
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V1-0.400
- IL6_JAK_STAT3_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.893 |
| 2 | TCGA-WA-A7H4-01A-21R-A34R-07 | — | — | 0.878 |
| 3 | SRR1313111 | — | A | 0.877 |
| 4 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.875 |
| 5 | X8de42096.ef3e.4864.8ee1.2ee7672c1c82 | — | cohortSQ1 | 0.869 |
| 6 | TCGA-CN-4737-01A-01R-1436-07 | — | — | 0.867 |
| 7 | fe036511-fe82-467c-9c6e-59bfb8b0a329 | — | — | 0.865 |
| 8 | ERR2208936 | — | — | 0.862 |
| 9 | TCGA-18-3409-01A-01R-0980-07 | — | cohortSQ1 | 0.859 |
| 10 | ERR2208903 | — | — | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |